CHAPTER 3.1 102 REFERENCES 1. Vogel B, Acevedo M, Appelman Y, Bairey Merz CN, Chieffo A, Figtree GA, et al. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. Lancet 2021;397:2385– 2438. doi:10.1016/S0140-6736(21)00684-X. 2. Lam CSP, Arnott C, Beale AL, Chandramouli C, Hilfiker-Kleiner D, Kaye DM, et al. Sex differences in heart failure. Eur Heart J 2019;40:3859–3868c. doi:10.1093/eurheartj/ehz835. 3. Beale AL, Meyer P, Marwick TH, Lam CSP, Kaye DM. Sex Differences in Cardiovascular Pathophysiology: Why Women Are Overrepresented in Heart Failure With Preserved Ejection Fraction. Circulation 2018;138:198–205. doi:10.1161/CIRCULATIONAHA.118.034271. 4. Lainščak M, Milinković I, Polovina M, Crespo-Leiro MG, Lund LH, Anker SD, et al. Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry. Eur J Heart Fail 2020;22:92–102. doi:10.1002/ejhf.1645. 5. Lawson CA, Zaccardi F, Squire I, Ling S, Davies MJ, Lam CSP, et al. 20-year trends in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: a population-based study. Lancet Public Health 2019;4:e406–e420. doi:10.1016/S2468-2667(19)30108-2. 6. Meyer S, van der Meer P, van Deursen VM, Jaarsma T, van Veldhuisen DJ, van der Wal MHL, et al. Neurohormonal and clinical sex differences in heart failure. European Heart Journal 2013;34:2538-+. doi:10.1093/eurheartj/eht152. 7. O’Meara E, Clayton T, McEntegart MB, McMurray JJV, Piña IL, Granger CB, et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2007;115:3111–3120. doi:10.1161/CIRCULATIONAHA.106.673442. 8. Stolfo D, Uijl A, Vedin O, Strömberg A, Faxén UL, Rosano GMC, et al. Sex-Based Differences in Heart Failure Across the Ejection Fraction Spectrum: Phenotyping, and Prognostic and Therapeutic Implications. JACC Heart Fail 2019;7:505–515. doi:10.1016/j.jchf.2019.03.011. 9. Greene SJ, DeVore AD, Sheng S, Fonarow GC, Butler J, Califf RM, et al. Representativeness of a Heart Failure Trial by Race and Sex. JACC: Heart Failure 2019;7:980–992. doi:10.1016/j.jchf.2019.07.011. 10. Tahhan AS, Vaduganathan M, Greene SJ, Fonarow GC, Fiuzat M, Jessup M, et al. Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review. JAMA Cardiol 2018;3:1011–1019. doi:10.1001/jamacardio.2018.2559. 11. Mentzer G, Hsich EM. Heart Failure with Reduced Ejection Fraction in Women: Epidemiology, Outcomes, and Treatment. Heart Fail Clin 2019;15:19–27. doi:10.1016/j.hfc.2018.08.003. 12. Norberg H. Clinical trial enrolment favours men: Fewer women meet eligibility criteria for trials of heart failure medication is discussed by Helena Norberg from Sweden. European Heart Journal 2019;40:1104–1105. doi:10.1093/eurheartj/ehz146. 13. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–3726. doi:10.1093/eurheartj/ehab368. 14. Veenis JF, Rocca H-PB-L, Linssen GCM, Erol-Yilmaz A, Pronk ACB, Engelen DJM, et al. Impact of sexspecific target dose in chronic heart failure patients with reduced ejection fraction. European Journal of Preventive Cardiology 2021;28:957–965. doi:10.1177/2047487320923185. 15. Santema BT, Ouwerkerk W, Tromp J, Sama IE, Ravera A, Regitz-Zagrosek V, et al. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. The Lancet 2019;394:1254–1263. doi:10.1016/S0140-6736(19)31792-1. 16. Michos ED, Reddy TK, Gulati M, Brewer LC, Bond RM, Velarde GP, et al. Improving the enrollment of women and racially/ethnically diverse populations in cardiovascular clinical trials: An ASPC practice statement. Am J Prev Cardiol 2021;8:100250. doi:10.1016/j.ajpc.2021.100250.
RkJQdWJsaXNoZXIy MjY0ODMw